Exploring hypertension genome-wide association studies findings and impact on pathophysiology, pathways, and pharmacogenetics

Wiley Interdisciplinary Reviews: Systems Biology and Medicine

Volumn 7, Issue 2, 2015, Pages 73-90

  Cabrera, Claudia P ^a,b   Ng, Fu Liang ^a   Warren, Helen R ^a,b   Barnes, Michael R ^a,b   Munroe, Patricia B ^a,b   Caulfield, Mark J ^a,b  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CYCLIN DEPENDENT KINASE 6; CYTOCHROME P450 1A1; CYTOCHROME P450 1A2; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENDOTHELIAL NITRIC OXIDE SYNTHASE; FURIN; HLA DQB1 ANTIGEN; HLA DRB1 ANTIGEN; HLA DRB3 ANTIGEN; METHYLENETETRAHYDROFOLIC ACID; MICRORNA; RAB11 PROTEIN; THIAZIDE DIURETIC AGENT; TRANSCRIPTION FACTOR GATA 4; TAMM HORSFALL GLYCOPROTEIN;

ALLELE; ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE; FOLLOW UP; GENE LINKAGE DISEQUILIBRIUM; GENE LOCUS; GENETIC ASSOCIATION; GENETIC RISK; GENETIC VARIABILITY; GENOTYPE; HUMAN; HYPERTENSION; MONOTHERAPY; NONHUMAN; PATHOPHYSIOLOGY; PHARMACOGENETICS; PLEIOTROPY; REVIEW; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM; ANIMAL; DEFICIENCY; GENETICS; METABOLISM; PATHOLOGY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

ANIMALS; GENETIC LOCI; GENOME-WIDE ASSOCIATION STUDY; HUMANS; HYPERTENSION; LINKAGE DISEQUILIBRIUM; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE; RENIN-ANGIOTENSIN SYSTEM; UROMODULIN;

EID: 84923249917     PISSN: 19395094     EISSN: 1939005X     Source Type: Journal    
DOI: 10.1002/wsbm.1290     Document Type: Review

References (82)

1. Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: analysis of worldwide data. Lancet 2005, 365:217-223. doi:10.1016/s0140-6736(05)17741-1.
2. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002, 360:1903-1913.
3. Munroe PB, Barnes MR, Caulfield MJ. Advances in blood pressure genomics. Circ Res 2013, 112:1365-1379. doi:10.1161/circresaha.112.300387.
4. Genome-wide association study of 14, 000 cases of seven common diseases and 3, 000 shared controls. Nature 2007, 447:661-678. doi:10.1038/nature05911.
5. Ehret GB, Munroe PB, Rice KM, Bochud M, Johnson AD, Chasman DI, Smith AV, Tobin MD, Verwoert GC, Hwang SJ, et al. Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk. Nature 2011, 478:103-109. doi:10.1038/nature10405.
6. Wain LV, Verwoert GC, O'Reilly PF, Shi G, Johnson T, Johnson AD, Bochud M, Rice KM, Henneman P, Smith AV, et al. Genome-wide association study identifies six new loci influencing pulse pressure and mean arterial pressure. Nat Genet 2011, 43:1005-1011. doi:10.1038/ng.922.
7. Hindorff L, MacArthur J, Morales J, Junkins H, Hall P, Klemm A, Manolio T. A Catalog of Published Genome-Wide Association Studies. Available at: http://www.genome.gov/gwastudies/. (Accessed August 12, 2014).
8. Takeuchi F, Isono M, Katsuya T, Yamamoto K, Yokota M, Sugiyama T, Nabika T, Fujioka A, Ohnaka K, Asano H, et al. Blood pressure and hypertension are associated with 7 loci in the Japanese population. Circulation 2010, 121:2302-2309. doi:10.1161/circulationaha.109.904664.
9. Kato N, Takeuchi F, Tabara Y, Kelly TN, Go MJ, Sim X, Tay WT, Chen CH, Zhang Y, Yamamoto K, et al. Meta-analysis of genome-wide association studies identifies common variants associated with blood pressure variation in east Asians. Nat Genet 2011, 43:531-538. doi:10.1038/ng.834.
10. Franceschini N, Fox E, Zhang Z, Edwards TL, Nalls MA, Sung YJ, Tayo BO, Sun YV, Gottesman O, Adeyemo A, et al. Genome-wide association analysis of blood-pressure traits in African-ancestry individuals reveals common associated genes in African and non-African populations. Am J Hum Genet 2013, 93:545-554. doi:10.1016/j.ajhg.2013.07.010.
11. Keating BJ, Tischfield S, Murray SS, Bhangale T, Price TS, Glessner JT, Galver L, Barrett JC, Grant SF, Farlow DN, et al. Concept, design and implementation of a cardiovascular gene-centric 50 k SNP array for large-scale genomic association studies. PLoS One 2008, 3:e3583. doi:10.1371/journal.pone.0003583.
12. Tragante V, Barnes MR, Ganesh SK, Lanktree MB, Guo W, Franceschini N, Smith EN, Johnson T, Holmes MV, Padmanabhan S, et al. Gene-centric meta-analysis in 87, 736 individuals of European ancestry identifies multiple blood-pressure-related loci. Am J Hum Genet 2014, 94:349-360. doi:10.1016/j.ajhg.2013.12.016.
13. Ganesh SK, Chasman DI, Larson MG, Guo X, Verwoert G, Bis JC, Gu X, Smith AV, Yang ML, Zhang Y, et al. Effects of long-term averaging of quantitative blood pressure traits on the detection of genetic associations. Am J Hum Genet 2014, 95:49-65. doi:10.1016/j.ajhg.2014.06.002.
14. Simino J, Shi G, Bis JC, Chasman DI, Ehret GB, Gu X, Guo X, Hwang SJ, Sijbrands E, Smith AV, et al. Gene-age interactions in blood pressure regulation: a large-scale investigation with the CHARGE, global BPgen, and ICBP consortia. Am J Hum Genet 2014, 95:24-38. doi:10.1016/j.ajhg.2014.05.010.
15. Newton-Cheh C, Larson MG, Vasan RS, Levy D, Bloch KD, Surti A, Guiducci C, Kathiresan S, Benjamin EJ, Struck J, et al. Association of common variants in NPPA and NPPB with circulating natriuretic peptides and blood pressure. Nat Genet 2009, 41:348-353. doi:10.1038/ng.328.
16. Ganesh SK, Tragante V, Guo W, Guo Y, Lanktree MB, Smith EN, Johnson T, Castillo BA, Barnard J, Baumert J, et al. Loci influencing blood pressure identified using a cardiovascular gene-centric array. Hum Mol Genet 2013, 22:1663-1678. doi:10.1093/hmg/dds555.
17. Johnson AD, Newton-Cheh C, Chasman DI, Ehret GB, Johnson T, Rose L, Rice K, Verwoert GC, Launer LJ, Gudnason V, et al. Association of hypertension drug target genes with blood pressure and hypertension in 86, 588 individuals. Hypertension 2011, 57:903-910. doi:10.1161/hypertensionaha.110.158667.
18. Levy D, Ehret GB, Rice K, Verwoert GC, Launer LJ, Dehghan A, Glazer NL, Morrison AC, Johnson AD, Aspelund T, et al. Genome-wide association study of blood pressure and hypertension. Nat Genet 2009, 41:677-687. doi:10.1038/ng.384.
19. Newton-Cheh C, Johnson T, Gateva V, Tobin MD, Bochud M, Coin L, Najjar SS, Zhao JH, Heath SC, Eyheramendy S, et al. Genome-wide association study identifies eight loci associated with blood pressure. Nat Genet 2009, 41:666-676. doi:10.1038/ng.361.
20. Johnson T, Gaunt TR, Newhouse SJ, Padmanabhan S, Tomaszewski M, Kumari M, Morris RW, Tzoulaki I, O'Brien ET, Poulter NR, et al. Blood pressure loci identified with a gene-centric array. Am J Hum Genet 2011, 89:688-700. doi:10.1016/j.ajhg.2011.10.013.
21. Ho JE, Levy D, Rose L, Johnson AD, Ridker PM, Chasman DI. Discovery and replication of novel blood pressure genetic loci in the Women's Genome Health Study. J Hypertens 2011, 29:62-69. doi:10.1097/HJH.0b013e3283406927.
22. Cho YS, Go MJ, Kim YJ, Heo JY, Oh JH, Ban HJ, Yoon D, Lee MH, Kim DJ, Park M, et al. A large-scale genome-wide association study of Asian populations uncovers genetic factors influencing eight quantitative traits. Nat Genet 2009, 41:527-534. doi:10.1038/ng.357.
23. Padmanabhan S, Melander O, Johnson T, Di Blasio AM, Lee WK, Gentilini D, Hastie CE, Menni C, Monti MC, Delles C, et al. Genome-wide association study of blood pressure extremes identifies variant near UMOD associated with hypertension. PLoS Genet 2010, 6:e1001177. doi:10.1371/journal.pgen.1001177.
24. McKenzie JK, McQueen EG. Immunofluorescent localization of Tamm-Horsfall mucoprotein in human kidney. J Clin Pathol 1969, 22:334-339.
25. Dulawa J, Kokot F, Kokot M, Pander H. Urinary excretion of Tamm-Horsfall protein in normotensive and hypertensive elderly patients. J Hum Hypertens 1998, 12:635-637.
26. Kottgen A, Hwang SJ, Larson MG, Van Eyk JE, Fu Q, Benjamin EJ, Dehghan A, Glazer NL, Kao WH, Harris TB, et al. Uromodulin levels associate with a common UMOD variant and risk for incident CKD. J Am Soc Nephrol 2010, 21:337-344. doi:10.1681/asn.2009070725.
27. - cotransporter (NKCC2) is facilitated by Tamm-Horsfall protein in a chloride-sensitive manner. J Biol Chem 2011, 286:30200-30210. doi:10.1074/jbc.M111.222968.
28. Graham LA, Padmanabhan S, Fraser NJ, Kumar S, Bates JM, Raffi HS, Welsh P, Beattie W, Hao S, Leh S, et al. Validation of uromodulin as a candidate gene for human essential hypertension. Hypertension 2014, 63:551-558. doi:10.1161/hypertensionaha.113.01423.
29. Trudu M, Janas S, Lanzani C, Debaix H, Schaeffer C, Ikehata M, Citterio L, Demaretz S, Trevisani F, Ristagno G, et al. Common noncoding UMOD gene variants induce salt-sensitive hypertension and kidney damage by increasing uromodulin expression. Nat Med 2013, 19:1655-1660. doi:10.1038/nm.3384.
30. Kobayashi Y, Hirawa N, Tabara Y, Muraoka H, Fujita M, Miyazaki N, Fujiwara A, Ichikawa Y, Yamamoto Y, Ichihara N, et al. Mice lacking hypertension candidate gene ATP2B1 in vascular smooth muscle cells show significant blood pressure elevation. Hypertension 2012, 59:854-860. doi:10.1161/hypertensionaha.110.165068.
31. Brenner R, Perez GJ, Bonev AD, Eckman DM, Kosek JC, Wiler SW, Patterson AJ, Nelson MT, Aldrich RW. Vasoregulation by the β1 subunit of the calcium-activated potassium channel. Nature 2000, 407:870-876. doi:10.1038/35038011.
32. Boedtkjer E, Praetorius J, Matchkov VV, Stankevicius E, Mogensen S, Fuchtbauer AC, Simonsen U, Fuchtbauer EM, Aalkjaer C. Disruption of Na+, HCO(3)(-) cotransporter NBCn1 (slc4a7) inhibits NO-mediated vasorelaxation, smooth muscle Ca(2)(+) sensitivity, and hypertension development in mice. Circulation 2011, 124:1819-1829. doi:10.1161/circulationaha.110.015974.
33. Austin C, Wray S. Extracellular pH signals affect rat vascular tone by rapid transduction into intracellular pH changes. J Physiol 1993, 466:1-8.
34. Zhang Y, Oltman CL, Lu T, Lee HC, Dellsperger KC, VanRollins M. EET homologs potently dilate coronary microvessels and activate BK(Ca) channels. Am J Physiol Heart Circ Physiol 2001, 280:H2430-2440.
35. Li Q, Zhang Q, Wang M, Liu F, Zhao S, Ma J, Luo N, Li N, Li Y, Xu G, et al. Docosahexaenoic acid affects endothelial nitric oxide synthase in caveolae. Arch Biochem Biophys 2007, 466:250-259. doi:10.1016/j.abb.2007.06.023.
36. Agbor LN, Walsh MT, Boberg JR, Walker MK. Elevated blood pressure in cytochrome P4501A1 knockout mice is associated with reduced vasodilation to omega-3 polyunsaturated fatty acids. Toxicol Appl Pharmacol 2012, 264:351-360. doi:10.1016/j.taap.2012.09.007.
37. Arora P, Wu C, Khan AM, Bloch DB, Davis-Dusenbery BN, Ghorbani A, Spagnolli E, Martinez A, Ryan A, Tainsh LT, et al. Atrial natriuretic peptide is negatively regulated by microRNA-425. J Clin Invest 2013, 123:3378-3382. doi:10.1172/jci67383.
38. Wu C, Gong Y, Sun A, Zhang Y, Zhang C, Zhang W, Zhao G, Zou Y, Ge J. The human MTHFR rs4846049 polymorphism increases coronary heart disease risk through modifying miRNA binding. Nutr Metab Cardiovasc Dis 2013, 23:693-698. doi:10.1016/j.numecd.2012.02.009.
39. Salvi E, Kuznetsova T, Thijs L, Lupoli S, Stolarz-Skrzypek K, D'Avila F, Tikhonoff V, De Astis S, Barcella M, Seidlerova J, et al. Target sequencing, cell experiments, and a population study establish endothelial nitric oxide synthase (eNOS) gene as hypertension susceptibility gene. Hypertension 2013, 62:844-852. doi:10.1161/hypertensionaha.113.01428.
40. Rotival M, Zeller T, Wild PS, Maouche S, Szymczak S, Schillert A, Castagne R, Deiseroth A, Proust C, Brocheton J, et al. Integrating genome-wide genetic variations and monocyte expression data reveals trans-regulated gene modules in humans. PLoS Genet 2011, 7:e1002367. doi:10.1371/journal.pgen.1002367.
41. Wright J, Mizutani S, Harding J. Pathways involved in the transition from hypertension to hypertrophy to heart failure. Treatment strategies. Heart Fail Rev 2008, 13:367-375. doi:10.1007/s10741-007-9060-z.
42. Kraja A, Hunt S, Rao DC, Dávila-Román V, Arnett D, Province M. Genetics of hypertension and cardiovascular disease and their interconnected pathways: lessons from large studies. Curr Hypertens Rep 2011, 13:46-54. doi:10.1007/s11906-010-0174-7.
43. Kanehisa M, Goto S, Sato Y, Kawashima M, Furumichi M, Tanabe M. Data, information, knowledge and principle: back to metabolism in KEGG. Nucleic Acids Res 2014, 42:D199-205. doi:10.1093/nar/gkt1076.
44. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA 2005, 102:15545-15550. doi:10.1073/pnas.0506580102.
45. Willoughby S, Holmes A, Loscalzo J. Platelets and cardiovascular disease. Eur J Cardiovasc Nurs 2002, 1:273-288. doi:10.1016/s1474-5151(02)00038-5.
46. Berridge MJ, Bootman MD, Roderick HL. Calcium signalling: dynamics, homeostasis and remodelling. Nat Rev Mol Cell Biol 2003, 4:517-529.
47. Andreassen OA, McEvoy LK, Thompson WK, Wang Y, Reppe S, Schork AJ, Zuber V, Barrett-Connor E, Gautvik K, Aukrust P, et al. Identifying common genetic variants in blood pressure due to polygenic pleiotropy with associated phenotypes. Hypertension 2014, 63:819-826. doi:10.1161/hypertensionaha.113.02077.
48. Sivakumaran S, Agakov F, Theodoratou E, Prendergast James G, Zgaga L, Manolio T, Rudan I, McKeigue P, Wilson James F, Campbell H. Abundant pleiotropy in human complex diseases and traits. Am J Hum Genet 2011, 89:607-618. doi:10.1016/j.ajhg.2011.10.004.
49. Donazzan L, Mahfoud F, Linz D, Ewen S, Ukena C, Böhm M. Novel and nonpharmacologic approaches to cardio-protection in hypertension. Curr Hypertens Rep 2014, 16:1-9. doi:10.1007/s11906-014-0430-3.
50. Hunt KA, Zhernakova A, Turner G, Heap GAR, Franke L, Bruinenberg M, Romanos J, Dinesen LC, Ryan AW, Panesar D, et al. Newly identified genetic risk variants for celiac disease related to the immune response. Nat Genet 2008, 40:395-402.
51. Gudbjartsson DF, Bjornsdottir US, Halapi E, Helgadottir A, Sulem P, Jonsdottir GM, Thorleifsson G, Helgadottir H, Steinthorsdottir V, Stefansson H, et al. Sequence variants affecting eosinophil numbers associate with asthma and myocardial infarction. Nat Genet 2009, 41:342-347.
52. Alcina A, Vandenbroeck K, Otaegui D, Saiz A, Gonzalez JR, Fernandez O, Cavanillas ML, Cenit MC, Arroyo R, Alloza I, et al. The autoimmune disease-associated KIF5A, CD226 and SH2B3 gene variants confer susceptibility for multiple sclerosis. Genes Immun 2010, 11:439-445.
53. Hinks A, Martin P, Flynn E, Eyre S, Packham J, Barton A, Childhood Arthritis Prospective Study UC, BSPAR study group, Worthington J, Thomson W. Investigation of type 1 diabetes and coeliac disease susceptibility loci for association with juvenile idiopathic arthritis. Ann Rheum Dis 2010, 69:2169-2172. doi:10.1136/ard.2009.126938.
54. Waterworth DM, Ricketts SL, Song K, Chen L, Zhao JH, Ripatti S, Aulchenko YS, Zhang W, Yuan X, Lim N, et al. Genetic variants influencing circulating lipid levels and risk of coronary artery disease. Arterioscler Thromb Vasc Biol 2010, 30:2264-2276. doi:10.1161/atvbaha.109.201020.
55. van Vliet-Ostaptchouk JV, den Hoed M, Luan J, Zhao JH, Ong KK, van der Most PJ, Wong A, Hardy R, Kuh D, van der Klauw MM, et al. Pleiotropic effects of obesity-susceptibility loci on metabolic traits: a meta-analysis of up to 37, 874 individuals. Diabetologia 2013, 56:2134-2146. doi:10.1007/s00125-013-2985-y.
56. Gottesman O, Drill E, Lotay V, Bottinger E, Peter I. Can genetic pleiotropy replicate common clinical constellations of cardiovascular disease and risk? PLoS One 2012, 7:e46419. doi:10.1371/journal.pone.0046419.
57. Denny JC, Ritchie MD, Basford MA, Pulley JM, Bastarache L, Brown-Gentry K, Wang D, Masys DR, Roden DM, Crawford DC. PheWAS: demonstrating the feasibility of a phenome-wide scan to discover gene-disease associations. Bioinformatics 2010, 26:1205-1210. doi:10.1093/bioinformatics/btq126.
58. Caulfield M, Munroe P, Pembroke J, Samani N, Dominiczak A, Brown M, Benjamin N, Webster J, Ratcliffe P, O'Shea S, et al. Genome-wide mapping of human loci for essential hypertension. Lancet 2003, 361:2118-2123. doi:10.1016/s0140-6736(03)13722-1.
59. Abraham G, Kowalczyk A, Zobel J, Inouye M. Performance and robustness of penalized and unpenalized methods for genetic prediction of complex human disease. Genet Epidemiol 2013, 37:184-195. doi:10.1002/gepi.21698.
60. Griffith M, Griffith OL, Coffman AC, Weible JV, McMichael JF, Spies NC, Koval J, Das I, Callaway MB, Eldred JM, et al. DGIdb: mining the druggable genome. Nat Methods 2013, 10:1209-1210. doi:10.1038/nmeth.2689.
61. Ghofrani HA, D'Armini AM, Grimminger F, Hoeper MM, Jansa P, Kim NH, Mayer E, Simonneau G, Wilkins MR, Fritsch A, et al. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension. N Engl J Med 2013, 369:319-329. doi:10.1056/NEJMoa1209657.
62. Ghofrani HA, Galie N, Grimminger F, Grunig E, Humbert M, Jing ZC, Keogh AM, Langleben D, Kilama MO, Fritsch A, et al. Riociguat for the treatment of pulmonary arterial hypertension. N Engl J Med 2013, 369:330-340. doi:10.1056/NEJMoa1209655.
63. Arnett DK, Claas SA. Pharmacogenetics of antihypertensive treatment: detailing disciplinary dissonance. Pharmacogenomics 2009, 10:1295-1307. doi:10.2217/pgs.09.61.
64. Peters BJ, Klungel OH, de Boer A, Ch Stricker BH, Maitland-van der Zee AH. Pharmacogenetics of cardiovascular drug therapy. Clin Cases Miner Bone Metab 2009, 6:55-65.
65. Turner ST, Schwartz GL, Chapman AB, Hall WD, Boerwinkle E. Antihypertensive pharmacogenetics: getting the right drug into the right patient. J Hypertens 2001, 19:1-11.
66. Arnett DK, Claas SA, Lynch AI. Has pharmacogenetics brought us closer to 'personalized medicine' for initial drug treatment of hypertension? Curr Opin Cardiol 2009, 24:333-339. doi:10.1097/HCO.0b013e32832c58ba.
67. Gong Y, McDonough CW, Wang Z, Hou W, Cooper-DeHoff RM, Langaee TY, Beitelshees AL, Chapman AB, Gums JG, Bailey KR, et al. Hypertension susceptibility loci and blood pressure response to antihypertensives: results from the pharmacogenomic evaluation of antihypertensive responses study. Circ Cardiovasc Genet 2012, 5:686-691. doi:10.1161/circgenetics.112.964080.
68. Verschuren JJ, Trompet S, Wessels JA, Guchelaar HJ, de Maat MP, Simoons ML, Jukema JW. A systematic review on pharmacogenetics in cardiovascular disease: is it ready for clinical application? Eur Heart J 2012, 33:165-175. doi:10.1093/eurheartj/ehr239.
69. Johnson JA. Advancing management of hypertension through pharmacogenomics. Ann Med 2012, 44(Suppl 1):S17-22. doi:10.3109/07853890.2011.653399.
70. Muthumala A, Drenos F, Elliott PM, Humphries SE. Role of β adrenergic receptor polymorphisms in heart failure: systematic review and meta-analysis. Eur J Heart Fail 2008, 10:3-13. doi:10.1016/j.ejheart.2007.11.008.
71. Lynch AI, Eckfeldt JH, Davis BR, Ford CE, Boerwinkle E, Leiendecker-Foster C, Arnett DK. Gene panels to help identify subgroups at high and low risk of coronary heart disease among those randomized to antihypertensive treatment: the GenHAT study. Pharmacogenet Genomics 2012, 22:355-366. doi:10.1097/FPC.0b013e3283516ff8.
72. Turner ST, Bailey KR, Fridley BL, Chapman AB, Schwartz GL, Chai HS, Sicotte H, Kocher JP, Rodin AS, Boerwinkle E. Genomic association analysis suggests chromosome 12 locus influencing antihypertensive response to thiazide diuretic. Hypertension 2008, 52:359-365. doi:10.1161/hypertensionaha.107.104273.
73. Turner ST, Boerwinkle E, O'Connell JR, Bailey KR, Gong Y, Chapman AB, McDonough CW, Beitelshees AL, Schwartz GL, Gums JG, et al. Genomic association analysis of common variants influencing antihypertensive response to hydrochlorothiazide. Hypertension 2013, 62:391-397. doi:10.1161/hypertensionaha.111.00436.
74. Duarte JD, Turner ST, Tran B, Chapman AB, Bailey KR, Gong Y, Gums JG, Langaee TY, Beitelshees AL, Cooper-Dehoff RM, et al. Association of chromosome 12 locus with antihypertensive response to hydrochlorothiazide may involve differential YEATS4 expression. Pharmacogenomics J 2013, 13:257-263. doi:10.1038/tpj.2012.4.
75. Turner ST, Bailey KR, Schwartz GL, Chapman AB, Chai HS, Boerwinkle E. Genomic association analysis identifies multiple loci influencing antihypertensive response to an angiotensin II receptor blocker. Hypertension 2012, 59:1204-1211. doi:10.1161/hyp.0b013e31825b30f8.
76. Hansson L, Hedner T, Lund-Johansen P, Kjeldsen SE, Lindholm LH, Syvertsen JO, Lanke J, de Faire U, Dahlof B, Karlberg BE. Randomised trial of effects of calcium antagonists compared with diuretics and β-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study. Lancet 2000, 356:359-365.
77. Hiltunen TP, Suonsyrja T, Hannila-Handelberg T, Paavonen KJ, Miettinen HE, Strandberg T, Tikkanen I, Tilvis R, Pentikainen PJ, Virolainen J, et al. Predictors of antihypertensive drug responses: initial data from a placebo-controlled, randomized, cross-over study with four antihypertensive drugs (The GENRES Study). Am J Hypertens 2007, 20:311-318. doi:10.1016/j.amjhyper.2006.09.006.
78. Barone C, Mousa SS, Mousa SA. Pharmacogenomics in cardiovascular disorders: steps in approaching personalized medicine in cardiovascular medicine. Pharmgenomics Pers Med 2009, 2:59-67.
79. Arnett DK, Boerwinkle E, Davis BR, Eckfeldt J, Ford CE, Black H. Pharmacogenetic approaches to hypertension therapy: design and rationale for the Genetics of Hypertension Associated Treatment (GenHAT) study. Pharmacogenomics J 2002, 2:309-317. doi:10.1038/sj.tpj.6500113.
80. Abecasis GR, Auton A, Brooks LD, DePristo MA, Durbin RM, Handsaker RE, Kang HM, Marth GT, McVean GA. An integrated map of genetic variation from 1, 092 human genomes. Nature 2012, 491:56-65. doi:10.1038/nature11632.
81. Collins R. What makes UK Biobank special? Lancet 2012, 379:1173-1174. doi:10.1016/s0140-6736(12)60404-8.
82. See http://www.genome.sph.umich.edu/wiki/Exome_Chip_Design for further details on the Exome chip (Ilumina, San Diego, CA and Affymetrix, Santa Clara, CA).